Ramandi Alireza, Diehl Anna-Mae, Sanyal Arun J, de Jong Ype P
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.
Department of Medicine, Duke University, Durham, North Carolina, USA.
Liver Int. 2025 May;45(5):e70091. doi: 10.1111/liv.70091.
Patatin-like phospholipase domain-containing 3 (PNPLA3) was the first gene identified through genome-wide association studies to be linked to hepatic fat accumulation. A missense variant, encoding the PNPLA3-148M allele, has since been shown to increase the risk for the full spectrum of steatotic liver disease (SLD), from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Despite extensive validation of this association and ongoing research into its pathogenic role, the precise mechanisms by which PNPLA3-148M contributes to the progression of SLD remain poorly understood. In this review, we evaluate preclinical in vitro and in vivo models used to investigate PNPLA3 and its involvement in SLD, with particular emphasis on metabolic dysfunction-associated steatotic liver disease. We assess the strengths and limitations of these models, as well as the challenges arising from species differences in PNPLA3 expression and function between human and murine systems.
含帕他丁样磷脂酶结构域蛋白3(PNPLA3)是首个通过全基因组关联研究确定与肝脏脂肪堆积相关的基因。此后发现,一种编码PNPLA3 - 148M等位基因的错义变体增加了从单纯性脂肪变性到脂肪性肝炎、肝硬化和肝细胞癌等全谱脂肪性肝病(SLD)的发病风险。尽管这一关联已得到广泛验证且对其致病作用的研究仍在进行,但PNPLA3 - 148M促进SLD进展的确切机制仍知之甚少。在本综述中,我们评估了用于研究PNPLA3及其在SLD中作用的临床前体外和体内模型,特别关注代谢功能障碍相关脂肪性肝病。我们评估了这些模型的优缺点,以及人类和小鼠系统中PNPLA3表达和功能的物种差异所带来的挑战。